NCT02448420
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody, Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy
Key Eligibility Criteria:
Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases:
Additional Notes:
Exclusions: Patients with untreated symptomatic brain metastases that require treatment- see trial for details
https://ClinicalTrials.gov/show/NCT02448420